# BIG-1 (NCT02416388)

> Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02416388
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: University Hospital, Angers
- Conditions: Acute Myeloid Leukemia (AML)
- Interventions: Idarubicin; Daunorubicin; HD Cytarabine; Cyclosporine; Methotrexate; Mycophenolic acid (MPA); vosaroxin; ID cytarabine; Dexamethasone; Venetoclax
- Enrollment: 3100
- Primary outcome: Overall survival
- Primary outcome: Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IV
- Primary outcome: Disease free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=big-1-nct02416388